Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 May;68(3):127–136. doi: 10.1016/j.curtheres.2007.06.002

Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus

John Thygesen 1,12, Reinhard Burk 2, Roberto Carassa 3, Andrew Crichton 4, Francisco Javier Goñi 5, Mitch Menage 6, Stefano Miglior 7, Donald Montgomery 8, John-Philippe Nordmann 9, Tim Roberts 10, Kuldev Singh 11
PMCID: PMC3967348  PMID: 24683204

Abstract

Abstract

Background:

In the clinical management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraocular pressure (IOP) and then maintain it over time at a level that preserves both the structure and function of the optic nerve.

Objective:

The objective of this report was to establish a consensus on the criteria that should be used to determine the characteristics of IOP-lowering medication.

Methods:

Discussion was held among a panel of 12 physicians considered to be experts in glaucoma to develop a consensus on the criteria used by them to determine the characteristics of the IOP-lowering medication chosen for initial monotherapy and adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development combined available evidence and the impressions of these physicians regarding the clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the panel identified the criteria, the order of priority and the relative importance of these criteria were then established in the setting of 3 risk categories (low, medium, and high) for a patient to experience significant visual disability from glaucoma over their expected life span.

Results:

The panel identified 5 criteria to determine the characteristics of IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, compliance/administration, and cost of treatment. IOP-lowering effect was consistently ranked as the highest priority and cost as the lowest. The priority of compliance/administration did not vary by clinical situation. Systemic AEs and ocular tolerability were ranked as higher priorities in initial monotherapy than in adjunctive treatment and ranked lower as the risk for visual disability increased. The priority given to the criteria used to determine clinical effectiveness varied both with the risk for functional vision loss from glaucoma and whether initial monotherapy or adjunctive treatment was being considered.

Conclusion:

Glaucoma treatment should be assessed with regard to the need not only to lower IOP but also to minimize systemic and ocular AEs, promote patient compliance, and minimize cost. The order of priority and relative importance given to these treatment criteria will vary as part of individualizing patient care.

Key Words: consensus, criteria, intraocular pressure, glaucoma

Full Text

The Full Text of this article is available as a PDF (129.1 KB).

References

  • 1.Sommer A, Katz J, Quigley HA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991;109:77–83. doi: 10.1001/archopht.1991.01080010079037. [DOI] [PubMed] [Google Scholar]
  • 2.Leske MC, Heijl A, Hussein M. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56. doi: 10.1001/archopht.121.1.48. for the Early Manifest Glaucoma Trial Group. [DOI] [PubMed] [Google Scholar]
  • 3.Leske MC, Connell AM, Wu SY. Incidence of open-angle glaucoma: The Barbados Eye Studies. Arch Ophthalmol. 2001;119:89–95. for the Barbados Eye Studies Group. [PubMed] [Google Scholar]
  • 4.Leske MC, Connell AM, Wu SY. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–924. doi: 10.1001/archopht.1995.01100070092031. [DOI] [PubMed] [Google Scholar]
  • 5.Kass MA, Heuer DK, Higginbotham EJ. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713. doi: 10.1001/archopht.120.6.701. discussion 829–830. [DOI] [PubMed] [Google Scholar]
  • 6.Heijl A, Leske MC, Bengtsson B. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268. for the Early Manifest Glaucoma Trial Group. [DOI] [PubMed] [Google Scholar]
  • 7.The AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440. doi: 10.1016/s0002-9394(00)00538-9. [DOI] [PubMed] [Google Scholar]
  • 8.Lichter PR, Musch DC, Gillespie BW. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953. doi: 10.1016/s0161-6420(01)00873-9. for the GIGTs Study Group. [DOI] [PubMed] [Google Scholar]
  • 9.Collaborative Normal-Tension Glaucoma Study Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505. doi: 10.1016/s0002-9394(98)00272-4. [DOI] [PubMed] [Google Scholar]
  • 10.Heithoff KA, Lohr KN. Effectiveness and Outcomes in Health Care: Proceedings of an Invitational Conference by the Institute of Medicine Division of Health Care Services. National Academies Press; Washington, DC: 1990. Promise and limitations of effectiveness and outcomes research. Summary statement of the IOM Core Committee; pp. 8–18. [PubMed] [Google Scholar]
  • 11.Weinreb RN, Friedman DS, Fechtner RD. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004;138:458–467. doi: 10.1016/j.ajo.2004.04.054. [DOI] [PubMed] [Google Scholar]
  • 12.Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–1720. doi: 10.1016/S0140-6736(04)16257-0. [DOI] [PubMed] [Google Scholar]
  • 13.European Glaucoma Society . 2nd ed. DOGMA Srl; Savona, Italy: 2003. Terminology and Guidelines for Glaucoma. [Google Scholar]
  • 14.South East Asia Glaucoma Interest Group . SEAGIG; Sydney, Australia: 2004. Asia Pacific Glaucoma Guidelines. [Google Scholar]
  • 15.American Academy of Ophthalmology . American Academy of Ophthalmology; San Francisco, Calif: 2003. Age-Related Macular Degeneration. Preferred Practice Pattern. [Google Scholar]
  • 16.Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14:752–756. doi: 10.1038/eye.2000.197. [DOI] [PubMed] [Google Scholar]
  • 17.Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: A qualitative study. J Ocul Pharmacol Ther. 2002;18:401–409. doi: 10.1089/10807680260362687. [DOI] [PubMed] [Google Scholar]
  • 18.Nordmann JP, Auzanneau N, Richard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75. doi: 10.1186/1477-7525-1-75. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES